COMPUGEN LTD(CGEN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,360 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
CGEN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for COMPUGEN LTD (CGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CGEN at 53.9/100 on a 32-signal composite quality model, placing it at rank #1,360 of 2,962 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), COMPUGEN LTD reports quarterly revenue of $72.8M, net income of $35.3M, an operating margin of 43.0%. Top institutional holders of CGEN by reported 13-F value include SILVERARC CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, MORGAN STANLEY, based on the most recent SEC filings. CGEN trades on the Nasdaq exchange and files with the SEC under CIK 1119774. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COMPUGEN LTD directly from SEC EDGAR. COMPUGEN LTD's 13F Pro composite quality score has ranged between 36 and 55 since 2026, currently 53.9 — an improving long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
FY 2025
$72.8M
Net Income
FY 2025
$35.3M
Free Cash Flow
FY 2025
$31.3M
Operating Margin
FY 2025
43.0%
ROIC
FY 2025
30.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+161.1% YoYNet Income
+348.4% YoYOperating Income
+310.4% YoYEPS (Diluted)
+337.5% YoYTotal Assets
+36.2% YoYOp. Cash Flow
-36.2% YoYFree Cash Flow
-36.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $72.8M +161.1% | $27.9M -16.7% | $33.5M +346.1% | $7.5M +25.0% | $6.0M +200.0% | $2.0M |
| Net Income | $35.3M +348.4% | $-14.2M +24.1% | $-18.8M +44.3% | $-33.7M +1.5% | $-34.2M -15.2% | $-29.7M |
| Operating Income | $31.3M +310.4% | $-14.9M -14.6% | $-13.0M +63.3% | $-35.4M -0.9% | $-35.1M -11.4% | $-31.5M |
| EPS (Diluted) | $0.38 +337.5% | $-0.16 +23.8% | $-0.21 +46.2% | $-0.39 +4.9% | $-0.41 -10.8% | $-0.37 |
| Total Assets | $156.6M +36.2% | $115.0M -5.2% | $121.3M +28.8% | $94.2M -28.7% | $132.2M -4.4% | $138.3M |
| Operating Cash Flow | $31.6M -36.2% | $49.6M +238.2% | $-35.9M -5.2% | $-34.1M -50.3% | $-22.7M +19.9% | $-28.3M |
| Free Cash Flow | $31.3M -36.7% | $49.5M +237.2% | $-36.1M -4.2% | $-34.6M -50.5% | $-23.0M +19.3% | $-28.5M |
Get alerted when CGEN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for COMPUGEN LTD including:
Top Institutional Holders of CGEN
SILVERARC CAPITAL MANAGEMENT, LLC
$6.8M3,184,257 shRENAISSANCE TECHNOLOGIES LLC
$4.0M1,877,500 shMORGAN STANLEY
$2.3M1,051,986 shNOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$2.2M1,020,000 shTaylor Frigon Capital Management LLC
$1.8M842,181 shARK Investment Management LLC
$1.7M786,536 shAltshuler Shaham Ltd
$1.1M521,625 shTWO SIGMA INVESTMENTS, LP
$1.1M512,419 shSTATE STREET CORP
$889.5K415,668 shAtom Investors LP
$649.5K303,526 sh
| Fund | Value | Shares |
|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | $6.8M | 3,184,257 |
| RENAISSANCE TECHNOLOGIES LLC | $4.0M | 1,877,500 |
| MORGAN STANLEY | $2.3M | 1,051,986 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $2.2M | 1,020,000 |
| Taylor Frigon Capital Management LLC | $1.8M | 842,181 |
| ARK Investment Management LLC | $1.7M | 786,536 |
| Altshuler Shaham Ltd | $1.1M | 521,625 |
| TWO SIGMA INVESTMENTS, LP | $1.1M | 512,419 |
| STATE STREET CORP | $889.5K | 415,668 |
| Atom Investors LP | $649.5K | 303,526 |
Companies Similar to CGEN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
InMode Ltd.
Protagonist Therapeutics, Inc
UTAH MEDICAL PRODUCTS INC
Lantheus Holdings, Inc.
UFP TECHNOLOGIES INC
ADMA BIOLOGICS, INC.
Embecta Corp.
PUMA BIOTECHNOLOGY, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CGEN on your watchlist
Track score changes the day COMPUGEN LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CGEN a good stock to buy?
13F Pro's AI-powered analysis of COMPUGEN LTD (CGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CGEN are available on the CGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CGEN is classified as a small company.
Which hedge funds own CGEN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of COMPUGEN LTD's investment landscape.